General Population clinical trials

Explore recruiting general population clinical trials.

Recruiting general population studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

General Population trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment with Inavolisib Combinations in Patients with Untreated, Early-Stage, PIK3CA-Mutated Breast Cancer

Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, Randomized, Open-Label Study Evaluating Two Inavolisib Dose Levels in Combination with Fulvestrant in Participants with PIK3CA-Mutated, HR-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Belgium, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulvestrant in Patients with Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8P Loss and Without a PIK3CA Mutation

France, Italy, Poland, Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Mechanisms of Action of Paradoxical Responses to Zolpidem: A Multimodal Study

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE III, OPEN-LABEL, MULTICENTER RANDOMIZED STUDY EVALUATING GLOFITAMAB AS A SINGLE AGENT VERSUS INVESTIGATOR’S CHOICE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Italy, France, Sweden, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy of simvastatin reducing liver fibrosis in patients with advanced fibrosis due to alcohol: a randomized, double-blind, placebo-controlled clinical trial.

Spain

Phase II and Phase III (Integrated) EU CTIS Study details

General Population trials by city

General Population in Toronto General Population in Vancouver General Population in Montreal General Population in Calgary General Population in Edmonton General Population in Ottawa General Population in Winnipeg General Population in Quebec City General Population in Hamilton General Population in Kitchener General Population in London General Population in Halifax General Population in New York General Population in Los Angeles General Population in Chicago General Population in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease